Sunshine Biopharma, Inc. (OTCPK:SBFM) entered into a share purchase agreement to acquire Atlas Pharma Inc. from Mohamed Belhaj for CAD 0.85 million on January 1, 2018. Under the terms, Sunshine Biopharma paid CAD 0.04 million and CAD 0.05 million in cash on December 20, 2017, issues 20 million shares and a promissory note in the principal amount of CAD 0.45 million, with interest payable at the rate of 3% per annum. Sunshine Biopharma is required to make payments of CAD 0.01 million per calendar quarter, due and payable on or before the end of each such calendar quarter through December 31, 2023. Atlas Pharma generated revenues of approximately CAD 0.5 million in 2017. Gilles Seguin of BCF LLP acted as legal advisor for Sunshine Biopharma. Sunshine Biopharma, Inc. (OTCPK:SBFM) completed the acquisition of Atlas Pharma Inc. on January 1, 2018.